CV6 Therapeutics

CV6 Therapeutics is a UK-based, private biotech founded in 2019, transitioning from an early-stage to a clinical-stage company. It is pioneering a novel approach targeting uracil-DNA metabolism to develop combination therapies that improve upon existing cornerstone treatments in large oncology and inflammatory disease markets. The company has initiated a Phase 1a trial for its lead oncology candidate and is preparing its inflammation candidate for the clinic, positioning itself in high-value therapeutic areas with significant unmet needs. Its strategy is built on a proprietary scientific platform with the potential for broad application across major disease areas.

First-in-class small molecule drugs targeting uracil-DNA metabolism, specifically inhibiting dUTPase to control abnormal cellular behavior and enhance standard-of-care treatments.

Operates in the highly competitive oncology and autoimmune disease spaces, competing against numerous large pharma and biotech companies with novel targeted therapies, immunotherapies, and combination regimens. Its differentiation lies in its unique uracil-DNA metabolism platform, but it must demonstrate superior or complementary efficacy to existing and emerging standards of care.